Navigation Links
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Date:12/19/2007

CRANBURY, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today positive results from its recently completed Phase 2 clinical trials of Amigal(TM) (migalastat hydrochloride) for Fabry disease. As of November 2007, Amigal is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases. The results will be discussed as a part of an "R&D Day" meeting being hosted by the company today from 4:30 to 7:00 PM at the Four Seasons Hotel in New York City. A live audio web cast of the presentation will be available to all interested parties through the Company's website at http://www.amicustherapeutics.com. Interested parties should connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An archive of the webcast will be available at the same address until approximately January 2, 2008.

"The completion of these trials is a major milestone for Amicus and these clinical results represent an important proof of concept for the pharmacological chaperone platform technology," said John F. Crowley, President and CEO of Amicus Therapeutics. "We look forward to advancing our program in Fabry as well as Gaucher, Pompe, and other important therapeutic targets utilizing this new approach to the treatment of a wide range of human genetic diseases."

Summary of Study Results:

The primary objective of the Phase 2 trials was to evalu
'/>"/>

SOURCE Amicus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2008)...wire-FirstCall/ -- Rigel,Pharmaceuticals, Inc. (N...gel,s,senior management team will host a conferen...mber 7, 2008, at 4:00 p.m. PST, to discuss the res...n oral Syk kinase inhibitor, in,patients with B-c...all and Webcast Information , To access the...
(Date:12/3/2008)... William Lehman Injury Research,Center (WLIRC), a...ated at the, University of Miami /Jackson Medical...lemedicine and Advanced Technology Research Center... the American Telemedicine Association (ATA) and,...e, today announced their,collaboration to expand ...
(Date:12/3/2008)...announces the exclusive licensing of DxS Scorpions...ganisms that reduce yields in biofuel fermentation...ontaminant microbes can increase profitability. ,...B) December 3, 2008 -- ETS has had the exclusive l... since 2005 and has developed numerous methods to ...
(Date:12/2/2008)...oengineering and Nanotechnology (IBN) have uncover...ch suggest that they could play a vital role in di... the redox properties of IMSs was published in the...n a separate study published in Angewandte Chemie...the first use of these salts to convert carbohydra...
Breaking Biology Technology:Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH 2Advanced Technologies and Wireless Telecommunications Enhance Care and Medical Training at the Ryder Trauma Center in Miami 2Advanced Technologies and Wireless Telecommunications Enhance Care and Medical Training at the Ryder Trauma Center in Miami 3Advanced Technologies and Wireless Telecommunications Enhance Care and Medical Training at the Ryder Trauma Center in Miami 4Advanced Technologies and Wireless Telecommunications Enhance Care and Medical Training at the Ryder Trauma Center in Miami 5Advanced Technologies and Wireless Telecommunications Enhance Care and Medical Training at the Ryder Trauma Center in Miami 6ETS Laboratories Offers New Process Optimization Tools to the Fuel Ethanol Industry 2New uses for imidazolium salts in medicine and alternative energy 2New uses for imidazolium salts in medicine and alternative energy 3
.... - The first-prize winner in the Governor,s Busin...artment of Commerce, according to a recent announc...ents pledge brings to $105,000 the amount already ...ontest which is accepting first-round applications... the Wisconsin Entrepreneurs, Conference in June. ...
...s. - The Wheaton Franciscan System and GE Medical ...lliance that extends their collaboration in the me...olic heath care and housing service provider, will...e Solutions; a portfolio of consulting, education ...customers in addition to the purchase of imaging a...
...a column last year, I commented on the growing gen...nd the world. Generic pharmaceuticals are not only.... There are a couple reasons why: , , 1) Numerou.... , , 2) The increased concern in the U.S. about...llion people in the U.S. who have no medical insur...
... The Wisconsin Innovation Network (WIN) Foundatio...nsins most vibrant high-tech regions, the Chippewa...subsidiary of the Wisconsin Technology Council, wh...hnology adviser to the Governor and the Legislatur...d Northeast Wisconsin, WIN is a networking group a...
Other Biology Technology:Business Plan Bounty Increases to $105,000 2The Coming of Biotech Generic Pharmaceuticals 2The Coming of Biotech Generic Pharmaceuticals 3The Coming of Biotech Generic Pharmaceuticals 4WIN Launches Chippewa Valley Chapter 2
(Date:12/3/2008)...r 14-17, 2008 at the University,s Sede Boqer campu...,s Jacob Blaustein Institutes for Desert Research ...re the United Nations Educational, Scientific and ...for Foreign Affairs, Jewish National Fund, the U.S...der in smart water solutions for agriculture. , ...
(Date:12/3/2008)...safe for pregnancy - other asthma drugs have not b... keep using the same asthma drugs they were using ...e best studied and can be regarded as safe. More t...owever. According to the German Institute for Qual...ta from trials could reassure women who worry abou...
(Date:12/3/2008)... to enable cheap, lifesaving new drugs to treat th...and to create innovative biofuels that can help so...and its applications are raising questions: Are s...ists purposely changing the definition of what is ...onally equipping terrorists with frightening new b...
(Date:12/2/2008)... easier than ever, but the amount of data to be an...gram now shows that genome sequence analysis can b...ers find hidden relationships in massive amounts o...ergy,s Pacific Northwest National Laboratory captu...puting ,08 High Performance Computing Analytics Ch...
Breaking Biology News(10 mins):Ben-Gurion University of the Negev to host 2Pregnant women with asthma can be more confident about some medicines 2Synthetic biology: Is ethics a showstopper? 2PNNL researchers earn top honors at Supercomputing conference 2PNNL researchers earn top honors at Supercomputing conference 3Woodland Park Care Center Earns Quality Respiratory Care Recognition 17190 1Woodland Park Care Center Earns Quality Respiratory Care Recognition 17190 2Huifeng Bio Pharmaceutical 28HFGB 29 Announces Participation in the 59th PHARMCHINA Expo 17188 1Huifeng Bio Pharmaceutical 28HFGB 29 Announces Participation in the 59th PHARMCHINA Expo 17188 2Aida Announces New Anti Cancer Drug Under Development 1852 1Aida Announces New Anti Cancer Drug Under Development 1852 2Chronic Exposure to Solvents Disturbs Brains Wiring 17186 1Chronic Exposure to Solvents Disturbs Brains Wiring 17186 2
...he past 50 years has declined, although the severi...December 27 issue of JAMA. , Stroke continues to b...0,000 new strokes occurring each year in the Unite...ehind heart disease and cancer and the leading neu...o background information in the article. Prior est...
...es, developmental biologists at the Kimmel Cancer ...hia may have discovered a new way that genes are t...ght, and the same processes are at work in higher ...ventually have implications for improving the unde...ood cancer. , Reporting in the journal Cell, Alex...
...n (UW) are working on an implantable electronic ch...n the part of the brain that controls movement. Th... 2, 2006, edition of Nature, showed such a device ...han a week. Strengthening of weak connections thro...ilitation of patients with brain injuries, stroke,...
...ine snail have gotten an unprecedented look at bra...es in even a simple sea creature are far from slug...rain cell of sea slug known as Aplysia, more than ...riting in Friday,s (Dec. 29, 2006) edition of the ...arning or the progression of brain disorders do no...
Other Biology News:Incidence of stroke decreases over last 50 years 2Jefferson researchers uncover new way nature turns genes on and off 2Electronic chip, interacting with the brain, modifies pathways for controlling movement 2How many genes does it take to learn? Lessons from sea slugs 2How many genes does it take to learn? Lessons from sea slugs 3
Mouse polyclonal antibody to REXO4 - XPMC2 prevents mitotic catastrophe 2 homolog (Xenopus laevis)
...a patented microwave process which makes a more hy...l attachment, increased cell growth and yields. Ce...difficult conditions, including reduced serum or s...re ecominic alternative to expensive and unstable ...
... specifically removes 20 of the most abundant prot... further proteomics analysis. This depletion enabl...ther you use one- or two-dimensional electrophores...o straight to mass spectrometry. This is based on ...
pLivSelect is a direct antibiotic-based selection system for recombinant identification. Recombinant selection depends solely on colony survival, eliminating the need for costly color screening. This
Biology Products: